Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. 1994

J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
Department of Immunohaematology and Blood Bank, University Hospital, Leiden, Netherlands.

In retrospective studies, perioperative blood transfusions were associated with poor prognosis after surgery for cancer and were a major independent risk factor for postoperative bacterial infection. Leucocyte-depleted, in contrast to buffy-coat-depleted, blood has no immunosuppressive effects in transplantation and so might lack detrimental effects on cancer prognosis and postoperative infections. We studied this hypothesis in a controlled trial by randomly allocating patients to receive either leucocyte-depleted red cells or packed cells without buffy coat when blood was needed. Between 1987 and 1990, 871 eligible patients with colorectal cancer, including 697 patients operated upon with curative intent, were randomised in the 16 participating hospitals. Neither the eligible group nor the curative group showed significant differences between the two trial transfusions in survival, disease-free survival, cancer recurrence rates, or overall infection rates after an average follow-up of 36 months. Patients who had a curative resection and who received blood of any sort had a lower 3-year survival than non-transfused patients (69% vs 81%, p = 0.001) and a higher infection rate (39% vs 24%, p < 0.001). Colorectal cancer recurrence rates, however, were not influenced by blood transfusion (30% vs 26%, p = 0.22). These combined observations confirm the association between blood transfusion and poor patient survival but indicate that the relation is not due to promotion of cancer.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007239 Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. Infection,Infection and Infestation,Infections and Infestations,Infestation and Infection,Infestations and Infections
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
November 1994, Lancet (London, England),
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
November 1994, Lancet (London, England),
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
November 1994, Lancet (London, England),
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
September 1996, Lancet (London, England),
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
January 2005, Lancet (London, England),
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
June 2003, Transfusion,
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
February 2011, Transfusion,
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
September 1995, British journal of haematology,
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
October 2013, Transfusion medicine (Oxford, England),
J G Houbiers, and A Brand, and L M van de Watering, and J Hermans, and P J Verwey, and A B Bijnen, and P Pahlplatz, and M Eeftinck Schattenkerk, and T Wobbes, and J E de Vries
January 2006, Ugeskrift for laeger,
Copied contents to your clipboard!